These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38166741)

  • 1. ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma.
    Xing T; Li L; Rao X; Zhao J; Chen Y; Ju G; Xu Y; Gao X; Dong G; Xia X; Guan Y; Zhang L; Wen Z; Liang J
    BMC Gastroenterol; 2024 Jan; 24(1):11. PubMed ID: 38166741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
    Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
    Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
    Li H; Wu K; Tao K; Chen L; Zheng Q; Lu X; Liu J; Shi L; Liu C; Wang G; Zou W
    Hepatology; 2012 Oct; 56(4):1342-51. PubMed ID: 22505239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT
    Yu L; Liu X; Wang X; Yan F; Wang P; Jiang Y; Du J; Yang Z
    Oncoimmunology; 2021; 10(1):1942673. PubMed ID: 34249476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.
    Hong B; Qian Y; Zhang H; Sang YW; Cheng LF; Wang Q; Gao S; Zheng M; Yao HP
    World J Gastroenterol; 2016 May; 22(18):4538-46. PubMed ID: 27182163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
    Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ
    World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
    Chung YL; Wu ML
    J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined identification of
    Zhao Y; Yang B; Chen D; Zhou X; Wang M; Jiang J; Wei L; Chen Z
    Aging (Albany NY); 2021 Feb; 13(3):4696-4712. PubMed ID: 33558447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.
    Qin SK; Li Q; Ming Xu J; Liang J; Cheng Y; Fan Y; Jiang J; Ye H; Tao H; Li L; Zheng L; Wei Z; Li S; Meng K; Ye B; Sun Y
    Cancer Sci; 2020 Nov; 111(11):4218-4231. PubMed ID: 32889778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B viral load affects prognosis of hepatocellular carcinoma.
    Yu SJ; Kim YJ
    World J Gastroenterol; 2014 Sep; 20(34):12039-44. PubMed ID: 25232241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.
    Li Z; Li N; Li F; Zhou Z; Sang J; Chen Y; Han Q; Lv Y; Liu Z
    Medicine (Baltimore); 2016 Dec; 95(52):e5749. PubMed ID: 28033288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma.
    Li Z; Li N; Li F; Zhou Z; Sang J; Jin Z; Liu H; Han Q; Lv Y; Liu Z
    Oncotarget; 2016 May; 7(18):26168-80. PubMed ID: 27034168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins.
    Hayashi S; Nagaoka K; Tanaka Y
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
    Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
    BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B Virus Small Envelope Protein Promotes Hepatocellular Carcinoma Angiogenesis via Endoplasmic Reticulum Stress Signaling To Upregulate the Expression of Vascular Endothelial Growth Factor A.
    Wu SX; Ye SS; Hong YX; Chen Y; Wang B; Lin XJ; Lin X
    J Virol; 2022 Feb; 96(4):e0197521. PubMed ID: 34910612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis.
    Chen W; Jiang J; Gong L; Shu Z; Xiang D; Zhang X; Bi K; Diao H
    J Exp Clin Cancer Res; 2021 Jan; 40(1):1. PubMed ID: 33390177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC.
    Dong J; Zhang R; Xia Y; Jiang X; Zhou K; Li J; Guo M; Cao X; Zhang S
    Front Immunol; 2023; 14():1142319. PubMed ID: 37180150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.